Titlebook: Biliary Tract and Gallbladder Cancer; A Multidisciplinary Joseph M. Herman,Timothy M. Pawlik,Charles R. Thom Book 2014Latest edition Sprin

Fulminate

HACK

Computed Tomography,act cancers. The biliary tract cancers are a combination of three distinct classes of tumors: (i) intrahepatic cholangiocarcinoma, (ii) proximal intrahepatic cholangiocarcinoma, and (iii) distal cholangiocarcinoma. These cancers share the unfortunate feature of having a poor prognosis unless surgica

鑒賞家

Interventional Radiology Management of Unresectable Intrahepatic Cholangiocarcinoma,ed series to prolong survival in these patients well beyond 1 year. Studies of drug-eluting bead transarterial chemoembolization (DEB-TACE) and yttrium-90 transarterial radioembolization (TARE) suggest longer survival may be achieved with these newer transarterial modalities. Research to date sugges

needle

Overview of Emerging Strategies in the Surgical Management of Biliary Tract Tumors,ladder cancer) tend to have advanced disease at presentation, with a median survival of about 6–9?months from the time of diagnosis [.]. Surgery with clear histologic margins (R0 resection) in combination with appropriate lymph node dissection is the only chance of cure with published five-year surv

確定的事

Surgical Management of Intra-Hepatic Cholangiocarcinoma,n unresectable disease due to vague or absent symptoms. Staging is based on tumor number, vascular invasion, extra-hepatic spread, lymph node involvement, and distant metastatic disease. When feasible, complete surgical resection offers the best hope of long-term survival, and may be approached via

Offbeat

寵愛

宏偉

Systemic Therapy: Current Strategies and New Directions,nitially with extensive unresectable disease, or will either develop recurrent disease after surgical resection. These patients will need systemic treatment with chemotherapy to palliate symptoms and prolong survival. Many challenges are faced with the development of effective chemotherapy regimens

狗舍

flavonoids

Israel as a Knowledge Economy II,vival following resection ranges from 17 to 44 %. The role of liver transplant is limited to select centers with clinical trials including rigorous neoadjuvant therapy. The role of adjuvant therapy is still being explored as newer, potentially more effective systemic agents are developed.